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Abstract
Introduction
Type 2 diabetes (T2D) is a major health priority worldwide and the majority of people with
diabetes live with multimorbidity (MM) (the co-occurrence of�2 chronic conditions). The
aim of this systematic review was to explore the association between MM and all-cause
mortality and glycaemic outcomes in people with T2D.
Methods
The search strategy centred on: T2D, MM, comorbidity, mortality and glycaemia. Databases
searched: MEDLINE, EMBASE, CINAHL Complete, The Cochrane Library, and SCOPUS.
Restrictions included: English language, quantitative empirical studies. Two reviewers inde-
pendently carried out: abstract and full text screening, data extraction, and quality appraisal.
Disagreements adjudicated by a third reviewer.
Results
Of the 4882 papers identified; 41 met inclusion criteria. The outcome was all-cause mortality
in 16 studies, glycaemia in 24 studies and both outcomes in one study. There were 28 longi-
tudinal cohort studies and 13 cross-sectional studies, with the number of participants rang-
ing from 96–892,223. Included studies were conducted in high or upper-middle-income
countries. Fifteen of 17 studies showed a statistically significant association between
increasing MM and higher mortality. Ten of 14 studies showed no significant associations
between MM and HbA1c. Four of 14 studies found higher levels of MM associated with
higher HbA1c. Increasing MM was significantly associated with hypoglycaemia in 9/10 stud-
ies. There was no significant association between MM and fasting glucose (one study). No
studies explored effects on glycaemic variability.
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Conclusions
This review demonstrates that MM in T2D is associated with higher mortality and hypogly-
caemia, whilst evidence regarding the association with other measures of glycaemic control
is mixed. The current single disease focused approach to management of T2D seems inap-
propriate. Our findings highlight the need for clinical guidelines to support a holistic approach
to the complex care needs of those with T2D and MM, accounting for the various conditions
that people with T2D may be living with.
Systematic review registration
International Prospective Register of Systematic Reviews CRD42017079500
Introduction
Type 2 diabetes (T2D) is a leading health priority. Over 424 million people live with diabetes
worldwide, leading to $727 billion US dollars in healthcare expenditure [1]. It is estimated that
four million people die from diabetes related causes every year, equivalent to one death every
eight seconds [1].
T2D management is complex and requires continuous efforts from both clinicians and
patients to implement recommendations for self-management and pharmacotherapy to
achieve evidence-based targets. For patients who have other chronic conditions in addition to
T2D, this complexity is amplified. This is important as T2D rarely occurs on its own–multi-
morbidity (MM) (presence of� 2 conditions) is the norm, with approximately 85% of those
living with T2D having at least one other chronic condition [2].
MM produces many challenges. It is associated with lower quality of life, increased costs, a
reduced ability to make lifestyle changes and may be associated with complex therapeutic regi-
mens [3], increasing the treatment burden experienced by the patient [4]. This in turn may
challenge and overwhelm individuals, resulting in reduced adherence and poorer outcomes
[4]. MM presents health professionals with increased workloads, and the clinical challenge of
interactions between multiple conditions and medications (4).
While MM brings about multiple challenges in a clinical sense, it also presents multiple
considerations from a conceptual perspective. The terms comorbidity and MM are often used
interchangeably [5]. Only more recently has there been a clearer understanding and distinc-
tion between the two terms. Comorbidity is defined as the occurrence or existence of an addi-
tional condition that co-occurs with an index disease [6]. MM however refers to the presence
of two or more chronic conditions in an individual, with no reference to an index condition
[7]. The former term illustrates the traditional approach to understanding T2D along with its
well-known micro- and macro-vascular complications. The latter term covers a different view
where a person’s overall illness burden is the focus and provides the basis for our systematic
review, which focuses on MM in people with T2D.
Despite MM presenting many challenges, there is no “gold standard” for the measurement
of MM [8]. We still lack clear and comprehensive criteria for the measurement of MM and
selection of chronic conditions that qualify for MM. As a result, a numerical count is an
acceptable form of measurement of MM, including particular scales (e.g. Charlson Comorbid-
ity Index) [9] that count particular conditions.
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Index.
MM is common in T2D and brings many challenges, yet currently little is understood
about the association between MM and outcomes in T2D. This systematic review seeks to
explore literature on the association between MM condition count in people with T2D and the
following two primary outcomes: 1) all-cause mortality; and 2) glycaemia (measured by
HbA1c). Secondary outcomes of interest include other measures of glycaemia: 1) hypoglycae-
mia, 2) hyperglycaemia; and 3) glycaemic variability.
Methods
Our detailed review protocol has been published elsewhere [10] and is summarised below.
We have followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
Protocols (PRISMA-P) guidelines [11] and our review is registered on the International Pro-
spective Register of Systematic Reviews (CRD42017079500).
Search strategy
A comprehensive search strategy was used to identify empirical quantitative studies with data
on associations between MM condition count and our outcomes of interest in people with
T2D. Target studies were observational studies that used either a cross-sectional or longitudi-
nal cohort design. The search was limited to papers published in English but there was no
restriction on publication date. A formal database search strategy was developed in consulta-
tion with a librarian (PC) from a biomedical library and members of our author group with
expertise in MM and T2D, using a combination of free text search and medical subject head-
ings; this is shown in S1 Text. Databases searched were MEDLINE (OVID interface), EMBASE
(OVID interface), CINAHL Complete (EBSCO interface), The Cochrane Library (OVID inter-
face), and SCOPUS. The search centred around five key concepts: T2D, MM, comorbidity, gly-
caemia and mortality. The search was carried out to include literature published up to 28th July
2017.
Inclusion/exclusion criteria
We included empirical quantitative studies that included data on associations between MM
condition count and adults with T2D and all-cause mortality or glycaemic outcomes. Full
details of inclusion and exclusion criteria for studies are shown in S1 Table and discussed in
detail elsewhere [10].
Data screening, extraction and analysis
The data screening process was conducted in three stages. Titles of identified studies in the
searches were screened by the primary researcher (JC) with a deliberately inclusive approach
to reduce the risk of missing potentially relevant studies. Abstract, full paper screening, data
extraction and quality appraisal were undertaken by two individual reviewers with any inter-
reviewer disagreements resolved by a third reviewer. Covidence [12], a systematic review man-
agement software, was used to store, share and assess papers, and undertake selection for
inclusion (beyond the title screen). Data were extracted in a structured manner using a prede-
fined data extraction form. Details of the data extraction instrument developed and used are
published elsewhere [10]. Data were analysed using a prespecified Population, Exposure, Com-
parator, Outcomes (PECO) framework which was an adapted framework based on the
Cochrane PICO statement where “I” for intervention is replaced with an “E” for exposure.
“Study Characteristics” were also included in the framework to take characteristics including
study design, setting, period of study, and aims and objectives into account. This PECO
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approach is acceptable as informed by the Cochrane Handbook [13] and has been utilised pre-
viously in a range of published systematic reviews [14, 15]. During data analysis and synthesis,
we grouped the included studies according to the two outcomes of interest (all-cause mortality
and glycaemia), further subgrouping the latter into different measures of glycaemia. We then
considered the implications of the overall findings for each of the outcomes, in order to iden-
tify knowledge gaps and clarify the key messages from the evidence, including implications for
future research and clinical guidelines for the management of people with T2D.
Quality appraisal
Quality appraisal was conducted by two reviewers independently. All studies were assessed
using the Newcastle-Ottawa quality assessment scale [16] which was informed by recommen-
dations from the Cochrane Handbook on assessing the quality of non-randomised studies
[13]. The Newcastle-Ottawa quality assessment scale utilises a star system to judge three broad
domains of the included studies: the selection of the study groups; the comparability of the
groups; and the ascertainment of the outcome of interest. We adapted the quality assessment
scale to suit our systematic review; shown in S2 Text. The Newcastle-Ottawa quality assess-
ment scale was designed so that it could be modified for specific systematic reviews for non-
randomised studies. For example, in the comparability domain, the scale asks the review
authors to select the two most important factors that the included studies should control for.
The scale’s face/content validity and inter-rater reliability have been established [16] and our
approach with the modified scale has been previously used in a published systematic review
[14]. Studies were not excluded based on the quality appraisal because our aim was to develop
a comprehensive understanding of the existing literature that explored associations between
MM and T2D.
Results
Retrieved studies
In total, 4,882 papers were identified with our search strategy, and 41 subsequently met our
inclusion criteria. Fig 1 demonstrates the inclusion and exclusion of papers at each stage of the
screening stages utilising the PRISMA flow diagram [11].
Included studies and their characteristics
We included 41 studies in our review. Twenty-four studies [17–40] had glycaemia as an out-
come, 16 studies [41–56] had all-cause mortality as an outcome and one study [57] included
both outcomes.
Key descriptive information of the included studies is summarised in Table 1 below. Partici-
pant numbers ranged from 96 to 892,223. There were 28 longitudinal cohort studies [18, 21,
28, 29, 32–37, 40–57] and 13 cross-sectional studies [17, 19, 20, 22–27, 30, 31, 38, 39]. All
included studies were conducted in high or upper-middle-income countries.
Measure of MM
The measure of MM condition count used in the included studies varied considerably. The
majority of studies (24/41 (59%)) [19, 21, 27, 28, 30–37, 39–41, 43, 46, 49–53, 55, 57] measured
MM in terms of the Charlson Comorbidity Index (CCI) [9]. MM was represented as a simple
count of conditions that were available in the study datasets in 15 studies (32%) [17, 18, 22–25,
29, 38, 44, 47, 48, 50, 52, 54, 56]. The remaining studies measured MM with other indices
including the chronic diseases score [20], cumulative illness rating scales [26], total illness
Multimorbidity in people with type 2 diabetes
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burden index [42], severity of illness index [45] and the Elixhauser index [52], or a combina-
tion of multiple MM measures [50, 52]. The measure of MM for each of the studies is summa-
rised in S2 Table. This further highlights the heterogeneity of included studies. Meta-analysis
was not possible due to variation in measurement of MM.
Only 11/41 (27%) [20, 26, 29, 38, 42, 43, 47, 50, 52, 54, 57] studies had the primary objec-
tives of exploring the relationship between MM and our outcomes of interest, however, all
included studies provided data about the association between MM and mortality or glycaemia.
9/41 (22%) studies [24, 27, 28, 33, 37, 39, 46, 49, 56] had broad scoping aims of determining
factors that were associated with mortality or glycaemia outcomes. More than half, 21/41
(51%) studies [17–19, 21–23, 25, 30–32, 34–36, 40, 41, 44, 45, 48, 51, 53, 55] did not state the
investigation of MM as a research objective, but contained MM count as a covariate when
exploring the impact of other factors on mortality or glycaemia, including data allowing us to
identify the association between MM count and our outcomes of interest. The research aims
included describing the effects of a range of factors (e.g. medication adherence, treatment
complexity, anti-diabetic oral treatment, treatment interactions, social support, economic bur-
den, obesity) on glycaemic control and mortality. This wide range of research objectives dem-
onstrates the heterogeneity of the included studies.
Description of the demographics of patients included in the studies is summarised in Table 2
below. The mean age of participants ranged from 38 to 83 years; this was unclear or could not
be calculated from the data provided in seven studies [23, 25, 27, 35, 38, 45, 48, 49]. Gender of
participants were not described in two studies [23, 49] and in those that did (n = 39) [17–22,
24–48, 50–57], the percentage of female ranged from 2% to 70%. Ethnicity was reported in 11
studies [19, 20, 24, 29, 31, 32, 39, 44, 45, 49, 53] and socioeconomic status was seldom reported
(n = 7) [29, 32, 38–40, 52, 54]. Full details of participants are shown in S2 Table.
Fig 1. PRISMA flow diagram.
https://doi.org/10.1371/journal.pone.0209585.g001
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Table 1. Summary of included studies.
Reference Outcome measure Country Study setting and design Number of
participants
MM measure
Both
Escalada J et al., 2016 All-cause mortality
Hypoglycaemic
event
US Community; cohort study N = 31,035 Charlson comorbidity index
All-cause
mortality
Castro-Rodriguez M
et al., 2016
All-cause mortality Spain Community; cohort study N = 363 Charlson comorbidity index
Greenfield S et al.,
2009
All-cause mortality Italy Diabetes outpatient clinic and
primary care; cohort study
N = 2,613 Total illness burden index
Huang YQ et al., 2014 All-cause mortality China Hospital; cohort study N = 533 Charlson comorbidity index
Hunt KJ et al., 2013 All-cause mortality US Veterans administrations; cohort
study
N = 892,223 Condition count
Kheirbek RE et al.,
2013
All-cause mortality US Veterans administrations; cohort
study
N = 17,773 Severity of illness index
Lin WH et al., 2015 All-cause mortality Taiwan Community; cohort study N = 65,559 Charlson comorbidity index
Lynch CP et al., 2014 All-cause mortality US Veterans administrations; cohort
study
N = 625,903 Condition count
Martin WG et al.,
2014
All-cause mortality Australia Hospital; cohort study N = 210 Condition count
McEwen LN et al.,
2012
All-cause mortality US Community; cohort study N = 8,334 Charlson comorbidity index
Monami M et al.,
2007
All-cause mortality Italy Hospital; cohort study N = 1,667 Charlson Comorbidity Index and Condition
Count
Monami M et al.,
2006
All-cause mortality Italy Hospital; cohort study N = 2,002 Charlson comorbidity index
Walker J et al., 2016 All-cause mortality Scotland Community; cohort study N = 126,648 Charlson Comorbidity Index, Elixhauser
Comorbidity Index and Condition Count
Wang CP et al., 2014 All-cause mortality US Veterans administrations; cohort
study
N = 2,415 Charlson comorbidity index
Weir DL et al., 2016 All-cause mortality US Community; cohort study N = 285,231 Condition count
Wilke T et al., 2015 All-cause mortality Germany Hospital; cohort study N = 35,661 Charlson comorbidity index
Zelada H et al., 2016 All-cause mortality Peru Hospital; cohort study N = 499 Condition count
Glycaemic
outcomes
Gallegos-Carrillo K
et al., 2009
Fasting plasma
glucose
Mexico Community; cross-sectional N = 666 Condition count
Abbatecola AM et al.,
2015
HbA1c Italy Nursing homes; cross-sectional N = 1,845 Condition count
Bae JP et al., 2016 HbA1c US Primary care; cross-sectional N = 248,567 Charlson comorbidity index
El-Kebbi IM et al.,
2001
HbA1c US Diabetes clinic; cross-sectional N = 823 Chronic disease score
Foran E et al., 2015 HbA1c Ireland Primary care; cross-sectional N = 283 Condition count
Fox KM et al., 2006 HbA1c UK Primary care; cross-sectional N = 11,866 Condition count
Frei A et al., 2012 HbA1c Switzerland Primary care; cross-sectional N = 326 Condition count
Hudon C et al., 2008 HbA1c Canada Primary care; cross-sectional N = 96 Cumulative illness rating scale
Luijks H et al., 2015 HbA1c Netherlands Primary care; cohort study N = 610 Condition count
Mosen DM et al.,
2017
HbA1c US Hospitals and outpatient; cross-
sectional
N = 19,600 Charlson comorbidity index
Pollack M et al., 2010 HbA1c US Community; cohort study N = 16,168 Charlson comorbidity index
Romero SP et al., 2013 HbA1c Spain Hospital; cohort study N = 1,519 Charlson comorbidity index
(Continued)
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Quality appraisal
The quality appraisal of the included studies is summarised in S2 Text. Generally, the papers
were of moderate to high quality based on the Newcastle-Ottawa quality assessment scale.
There were 12 (29%) papers assessed as representative of the general T2D population as they
were based on large national datasets. Furthermore, under the comparability domain, only 10
(24%) of the 41 included studies considered both age and known duration of diabetes in their
data analyses.
All-cause mortality
We identified 17/41 studies [41–57] that included sufficient data to explore the association
between MM condition count and all-cause mortality. All but two studies [41, 52] demon-
strated that increasing MM count is associated with statistically significant increased odds
ratios (ORs) or hazard ratios (HRs) of death. Studies differed in the analytic methods used to
determine the relationship between MM and mortality. These included: two-sample t-test to
compare MM between surviving and non-surviving participants; multivariable logistic regres-
sion models; and multivariable Cox proportional hazard models. Furthermore, MM was
treated in analysis either as a continuous or categorical variable in different studies. For studies
that showed a significant increase in mortality whilst treating increasing MM as a continuous
variable, the HRs from Cox proportional hazard models that explored MM represented by
CCI ranged from 1.22 to 1.95 [50, 51, 53, 55]. Whilst the study that represented MM as total ill-
ness burden index, the HR was 1.02 [42]. Studies that reported MM in categories presented
more difficulties in comparing the results because they differed in the MM categories that
were treated as reference groups [43–49, 54, 56]. This varied from treating 0 conditions, 1 con-
dition, 0–2 CCI and 1–2 CCI as reference in the analyses. The OR results therefore also varied
greatly. The OR for mortality was 1.26 for having 1+ conditions in addition to T2D when 0
Table 1. (Continued)
Reference Outcome measure Country Study setting and design Number of
participants
MM measure
Svensson E et al., 2016 HbA1c Denmark Community; cohort study N = 38,418 Charlson comorbidity index
Teljeur C et al., 2013 HbA1c Ireland Primary care; cross-sectional N = 424 Condition count
Walker RJ et al., 2015 HbA1c US Primary care; cross-sectional N = 615 Charlson comorbidity index
Abbatecola AM et al.,
2015
Hypoglycaemic
event
Italy Nursing homes; cohort study N = 2,258 Condition count
Fonseca V et al., 2017 Hypoglycaemic
event
US Community; cohort study N = 18,918 Charlson comorbidity index
Kim HM et al., 2016 Hypoglycaemic
event
Korea Community; cross-sectional N = 307,170 Charlson comorbidity index
Kostev K et al., 2014 Hypoglycaemic
event
Germany Primary care; cohort study N = 32,545 Charlson comorbidity index
McCoy RG et al., 2013 Hypoglycaemic
event
US Primary care and specialty practices;
cross-sectional
N = 326 Charlson comorbidity index
Quilliam BJ et al.,
2011
Hypoglycaemic
event
US Hospital; nested case control study N = 14,729 Charlson comorbidity index
Rathmann W et al.,
2013
Hypoglycaemic
event
Germany Primary care; cohort study N = 50,294 Charlson comorbidity index
Signorovitch JE et al.,
2013
Hypoglycaemic
event
US Community; cohort study N = 33,492 Charlson comorbidity index
Yu HC et al., 2014 Hypoglycaemic
event
Taiwan Hospital; cohort study N = 399,252 Charlson comorbidity index
https://doi.org/10.1371/journal.pone.0209585.t001
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Table 2. Participant demographics.
Reference Outcome
measure
No of participants and
gender % F = female
M = male
Mean (SD)
age in years
Ethnicity Socioeconomic status
Both
Escalada J et al.,
2016
All-cause
mortality
Hypoglycaemic
event
31035 (53%F 37%M) 72 (9.2) Not reported Not reported
All-cause
mortality
Castro-Rodriguez
M et al., 2016
All-cause
mortality
363 (54.8%F 45.2%M) 76 Not reported Not reported
Greenfield S
et al., 2009
All-cause
mortality
2613 (54.8%F 45.2%M) 62.8 Not reported Not reported
Huang YQ et al.,
2014
All-cause
mortality
533 (43.4%F 56.6%M) 65.2 (10.8) Not reported Not reported
Hunt KJ et al.,
2013
All-cause
mortality
892223 (2.4%F 97.6%
M)
66.2 (11.15) Non-Hispanic White 61.5%,
Non-Hispanic Black 12.1%,
Hispanic 13.9%, Other 12.5%
Not reported
Kheirbek RE
et al., 2013
All-cause
mortality
17773 (4.8%F 95.2%M) Unclear White 26.1%, Hispanic 29.9%,
Unclear 44%
Not reported
Lin WH et al.,
2015
All-cause
mortality
65559 (47.9%F 52.1%
M)
60.5 (12.9) Not reported Not reported
Lynch CP et al.,
2014
All-cause
mortality
625903 (2.2%F 97.8%
M)
65 (11.1) Non-Hispanic Black 72.1%, Non-
Hispanic White 13.2%, Hispanic
5.3%, Other/Unknown race 9.4%
Not reported
Martin WG et al.,
2014
All-cause
mortality
210 (42.9%F 57.1%M) Unclear Not reported Not reported
McEwen LN
et al., 2012
All-cause
mortality
8334 (Gender unclear) Unclear Non-Hispanic White 50%,
Hispanic 15%, African American
18%, Asian/Pacific Islander 9%,
Other 8%
Unclear–was included in analysis but not described
Monami M et al.,
2007
All-cause
mortality
1667 (49.3%F 50.7%M) 65.7 (11.0) Not reported Not reported
Monami M et al.,
2006
All-cause
mortality
2002 (50.1%F 49.9%M) 65.8 (10.8) Not reported Not reported
Walker J et al.,
2016
All-cause
mortality
126648 (44.6%F 55.4%
M)
61.9 Not reported Q1 (most deprived) 23.2%, Q2 22.7%, Q3 20.4, Q4
18.6%, Q5 15.1%
Wang CP et al.,
2014
All-cause
mortality
2415 (2%F 98%M) 73.7 White/others 83%, Hispanic 7%,
Black 10%
Not reported
Weir DL et al.,
2016
All-cause
mortality
285231 (49.1%F 50.9%
M)
53 (10.5) Not reported Mean (SD) income in USD $48842 (6567)
Wilke T et al.,
2015
All-cause
mortality
35661 (54.2%F 45.8%
M)
65.91 Not reported Not reported
Zelada H et al.,
2016
All-cause
mortality
499 (63.6%F 36.4%M) 61.6 (13.8) Not reported Not reported
Glycaemic
outcomes
Gallegos-Carrillo
K et al., 2009
Fasting plasma
glucose
666 (64.7%F 35.3%M) Unclear Not reported Not reported
Abbatecola AM
et al., 2015
HbA1c 1845 (70%F 30%M) 82 (8) Not reported Not reported
Bae JP et al., 2016 HbA1c 248567 (50.9%F 49.1%
M)
64 (med) Caucasian 66.5%, African
American 14.3%, Asian 2.8%,
Other 16.4%
Not reported
(Continued)
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conditions was the reference group [54], whilst the OR for mortality was 5.46 for CCI of 5
+ when CCI of 1–2 was the reference group [43]. The HR results also varied extensively. When
CCI of 0–2 was the reference group, the HR for CCI of 3–4 was 1.4 [46]. When having 1
Table 2. (Continued)
Reference Outcome
measure
No of participants and
gender % F = female
M = male
Mean (SD)
age in years
Ethnicity Socioeconomic status
El-Kebbi IM
et al., 2001
HbA1c 823 (65%F 35%M) 53 (1) African American 90%, Unclear
10%
Not reported
Foran E et al.,
2015
HbA1c 283 (42%F 58%M) 68 (9.5) Not reported Not reported
Fox KM et al.,
2006
HbA1c 11866 (Gender
unclear)
Unclear Not reported Not reported
Frei A et al., 2012 HbA1c 326 (42.6%F 57.4%M) 67.1 (10.6) Swiss 91.8%, Unclear 8.2% Not reported
Hudon C et al.,
2008
HbA1c 96 (51%F 49%M) 66.99 Not reported Not reported
Luijks H et al.,
2015
HbA1c 610 (52%F 48%M) 63 (12.5) Not reported Low 52.1%, Middle 40%, High 7.9%
Mosen DM et al.,
2017
HbA1c 19600 (48%F 52%M) 63.1 White 78.9%, Hispanic 7.4%,
Asian American/Pacific Islander
6.5%, African American 3.9%,
Other 3.3%
Not reported
Pollack M et al.,
2010
HbA1c 16198 (44.1%F 55.9%
M)
52.8 Caucasian 77%, African
American 6%, Hispanic 4.3%,
Unclear 12.7%
At least 50% had a yearly income >US$65,000 and a
net worth of at least US$100,000
Romero SP et al.,
2013
HbA1c 1519 (54.2%F 45.8%M) 71.4 (7.6) Not reported Not reported
Svensson E et al.,
2016
HbA1c 38418 (44%F 56%M) 63 Not reported Not reported
Teljeur C et al.,
2013
HbA1c 424 (46.5%F 53.5%M) Unclear Not reported Low 40.1%, Unclear 59.9%
Walker RJ et al.,
2015
HbA1c 615 (38.4%F 61.6%M) 61.3 (10.9) Non-Hispanic Black 64.9%, Non-
Hispanic White 33%, Other/
Hispanic 2.1%
Annual income (USD) <$10k 20.2%, $10k-14.9k
11.3%, $15k-19.9k 10.1%, $20k-24.9k 10.4%, $25k-
34.9k 14.7%, $35k-49.9k 13.8%, $50k-74.9k 10.1%,
$75k+ 9.4%
Abbatecola AM
et al., 2015
Hypoglycaemic
event
2258 (69%F 31%M) 83 (7) Not reported Not reported
Fonseca V et al.,
2017
Hypoglycaemic
event
18918 (48%F 52%M) 64 (13) Not reported Not reported
Kim HM et al.,
2016
Hypoglycaemic
event
307170 (58.3%F 41.7%
M)
Unclear Not reported Not reported
Kostev K et al.,
2014
Hypoglycaemic
event
32545 (49.7%F 50.3%
M)
70.2 (11.2) Not reported Not reported
McCoy RG et al.,
2013
Hypoglycaemic
event
326 (44.5F% 55.5%M) 69.3 (12.0) Not reported Not reported
Quilliam BJ et al.,
2011
Hypoglycaemic
event
14729 (46.5%F 53.5%
M)
54.8 Not reported Not reported
Rathmann W
et al., 2013
Hypoglycaemic
event
50294 (47.1%F 52.9%
M)
67.3 Not reported Not reported
Signorovitch JE
et al., 2013
Hypoglycaemic
event
33492 (45.3%F 54.7%
M)
59.7 Not reported Not reported
Yu HC et al.,
2014
Hypoglycaemic
event
399252 (47.4%F 52.6%
M)
54.96
(12.51)
Not reported Monthly salary (NTD), dependants 24.6%,�$17280
4.9%, $17281–22800 37.1%, $22801–28800 15.7%,
$28801–36300 5.1%, $36301–45800 6.3%, $45801–
57800 2.5%, $57801 3.8%
https://doi.org/10.1371/journal.pone.0209585.t002
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condition in addition to T2D was the reference group, the HR for having 3+ conditions was
21.12 [56]. Despite the heterogeneity of the studies, it is evident that increasing MM count,
irrespective of the measure used, is associated with increased all-cause mortality. A summary
of the results can be found in S3 Table.
Glycaemia
We identified 25 studies [17–40, 57] that explored associations between MM condition count
and glycaemic outcomes. Fourteen studies [17, 19, 20, 22–24, 26, 29, 31, 32, 35, 37–39]
reported HbA1c, 10 studies [18, 21, 27, 28, 30, 33, 34, 36, 40, 57] hypoglycaemia, and one study
[25] measured glycaemia in terms of fasting plasma glucose. All results of the included studies
are summarised in S3 Table.
HbA1c. The majority of studies (10/14)[17, 20, 22–24, 26, 29, 31, 35, 38] showed no asso-
ciation with MM count while four studies [19, 32, 37, 39] found that increased MM count was
associated with higher HbA1c. These four studies used different methods of data analysis (S3
Table). Heterogeneity was also seen in the analysis of the effect on HbA1c (continuous for the
linear regression model but categorical for the remaining statistical methods).
Hypoglycaemia. An increase in MM count was significantly associated with hypoglycae-
mia in nine of the 10 included studies that presented hypoglycaemia as a glycaemic outcome
[18, 21, 27, 28, 33, 34, 36, 40, 57]. Nine of these studies presented MM in terms of the CCI.
However, the analysis of data differed greatly (S3 Table). For those that treated MM as a con-
tinuous variable using the CCI, the ORs for hypoglycaemia ranged from 1.06 to 1.37 per 1 unit
increase in CCI [28, 33]. Similar to the mortality studies, the hypoglycaemia studies that
reported MM in categories also presented difficulties in comparing the results due the various
reference categories used. One study that used logistic regression models categorised CCI into
1 (reference group), 2, 3, 4 and 5+ with ORs for hypoglycaemia of 1.00, 1.31, 1.81, 2.49 and
4.80, respectively [27]. Another study that used Cox proportional hazard models categorised
CCI into 0 (reference group), 1, 2, 3, 4 and 5+; the results showed HRs of 1.00, 1.04, 1.22, 1.16,
1.34 and 1.38, respectively [40]. Despite this heterogeneity, it is evident in the included studies
that an increase in MM count is associated with a significantly increased risk of
hypoglycaemia.
Fasting plasma glucose. One study explored the relationship between MM count and gly-
caemia as a continuous measure of fasting plasma glucose [25]. The study used a multivariable
linear regression model to investigate the association between increasing number of conditions
and fasting plasma glucose, and found no statistically significant association.
Glycaemic variability. No study reported glycaemic variability as an outcome measure
when exploring the relationship between MM count and glycaemia.
Study heterogeneity
Heterogeneity of the included studies can be seen in multiple aspects. It arises from the multi-
ple MM measures used in the included studies, the treatment of MM in data analysis either as
continuous or categorical variables and the different statistical analyses used. This is summa-
rised in Figs 2 and 3. As a result, meta-analysis and sub-group analysis are not possible.
Discussion
Summary of results
To the best of our knowledge, this is the first systematic review to synthesise the existing evi-
dence on associations between MM, all-cause mortality and glycaemia in people with T2D.
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The key findings from our review were that increased MM condition count in those with
T2D is significantly associated with all-cause mortality and hypoglycaemia. However, the evi-
dence of effects on other measures of glycaemia including HbA1c and fasting plasma glucose
is mixed. No studies explored the associations of MM with glycaemic variability.
How this fits in with current knowledge
Our findings are consistent with previous literature where increasing MM has been shown to
be associated with increased mortality in people with T2D [58–60]. Our findings demonstrated
this in a range of settings, countries and study sample sizes. Furthermore, despite variations in
the methodologies, measures of MM and statistical analyses, the evidence still suggests an
increase in risk of death with increasing MM.
We found no convincing evidence of an association between MM count and HbA1c. This
was unexpected as it has been well-established that HbA1c is an important clinical outcome to
consider in people with T2D and glycaemic management is a key component of clinical guide-
lines for T2D. This suggests that the association of MM with mortality that we identified is not
necessarily strongly mediated by glycaemia. Studies that have explored the relationship
Fig 2. Summary of all-cause mortality outcome papers.
https://doi.org/10.1371/journal.pone.0209585.g002
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between HbA1c and mortality showed conflicting results where some studies suggested that
increased HbA1c was significantly associated with increased mortality [61, 62] however,
another demonstrated that the use of intensive therapy to target HbA1c levels below 6.0%
increased the rate of death [63]. This mixed picture regarding the relationship between MM
count and HbA1c highlights the need for future research to examine how people with T2D
and their health professionals approach glycaemic management and targets in the context of
MM. It is recognised in many clinical guidelines that HbA1c targets should be individualised
based on factors such as age, diabetes duration and MM conditions [64, 65].
We found a significant association between MM and hypoglycaemia with 9/10 studies dem-
onstrating this. Previous studies have suggested that the presence of coexisting conditions may
increase a person’s vulnerability to both adverse clinical outcomes, including death, and severe
hypoglycaemia [66, 67]. This hypoglycaemia could be as a result of over-treatment or intensive
treatment for those that are less healthy (i.e. with greater MM), but a key paper from the
Action to Control Cardiovascular Risk in Diabetes (ACCORD) study showed that mortality
among those that reported hypoglycaemia was higher for those receiving standard treatment
than those receiving intensive treatment [68]. Hypoglycaemia could be a mediating factor for
Fig 3. Summary of glycaemic outcomes papers.
https://doi.org/10.1371/journal.pone.0209585.g003
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those with increased MM who ultimately have an increased risk of death. It is interesting to
note that the one study [30] in our review that reported no association between MM and hypo-
glycaemia, used self-report hypoglycaemia as an outcome, which was highlighted as a study
limitation, as hypoglycaemia awareness may be impaired and / or patient recall may be inaccu-
rate [69, 70].
Another key finding is that despite our comprehensive search of the literature, there was no
study that explored the effects of MM count on glycaemic variability. Glycaemic variability,
which refers to fluctuations in blood (or interstitial fluid) glucose levels, is a relatively new
measure of glycaemia in people with T2D. There is growing interest in targeting reduced gly-
caemic variability as an independent clinical goal because higher glucose variability is thought
to be associated with the development of chronic diabetes complications [71]. It is clear that
there is a need for new knowledge to be generated to further understand the association
between glycaemic variability and MM, and whether it will be clinically important or just
another surrogate marker with little clinical importance to people with T2D.
Methodological findings and implications
The studies included in our review were highly heterogenous, particularly in the way that MM
was measured. There is no consensus as to what is the best method to measure MM, and which
is most appropriate to use to predict mortality and other clinical outcomes. Monami et al, how-
ever, demonstrated that using a condition count was not inferior to the more complex CCI
(which applies weightings to the count) when predicting mortality in people with T2D [50].
The attribution of different weights to comorbidities, based on the severity, in the CCI does not
seem to add prognostic value in predicting mortality relative to a simple condition count. More-
over, as evident in our findings, increasing counts of conditions and other indices other than
the CCI can also be significant predictors of all-cause mortality in people with T2D. Although
our findings suggest that various measures of MM showed significant associations with
increased mortality, we cannot identify the best measure of MM in predicting mortality. Nor
can we identify the type of multimorbid conditions that could have stronger associations with
mortality and glycaemia. Piette and Kerr have recommended that multimorbid conditions
should be qualitatively assessed as concordant (related to T2D) or discordant (unrelated to
T2D) [72] and argue that condition counts are insufficient in describing MM. Therefore, the
implications for future research are that well-designed comparative studies of separate measures
including concordant and discordant conditions are warranted using large international data-
sets. Finally, while it will be essential to understand what patterns of MM are associated with the
worst outcomes it will also be important to investigate the mechanisms underpinning the
increased mortality experienced by those with T2D and MM. Importantly, it will be essential to
explore to what extent poor outcomes are explained by biology and how much is a result of
health-care systems that may be fragmented and failing to provide coordinated, supportive and
holistic care, tailored to the needs of people with complex health care problems [73].
Strengths and limitations
Key strengths of our review are our adherence to the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses Protocols (PRISMA-P) guidelines, our comprehensive search
strategy, and that all screening and data extraction were performed by two reviewers
independently.
We restricted our search to studies in the English language, which might be viewed as a lim-
itation, although there is increasing evidence that this is unlikely to be a particular problem
[74]. We did not apply any geographical limitations, and our review included studies from a
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variety of countries, all of which were high-income countries or upper-middle-income coun-
tries according to the United Nations country classifications. However, there were no studies
conducted in low-income countries. We also recognise the limitation of cross-sectional studies
in terms of assessment of temporality however, cross-sectional studies provide a snapshot of
the relationship between MM count and glycaemia related outcomes of interest.
Important strengths of our review are that we conducted an exhaustive search of five elec-
tronic databases and our tight inclusion and exclusion criteria allowed us to gather any data
that explored associations between MM and our outcomes of interest, even if the study did not
specifically aim to explore this relationship.
A major advantage of our review is that it brings together information about the effects of
MM in people with T2D from various sources to create a comprehensive picture of its effects
on a number of outcomes. However, one limitation is that the included studies and therefore
study participants were highly heterogenous, making comparisons between studies difficult,
which prevented meta-analyses and limited us to a narrative synthesis. The large variation
arose from the many ways MM is defined, the way outcomes are reported and the varying
methods of statistical analyses. Another limitation of our review is that we did not explore the
effects of specific multimorbid conditions on our outcomes of interest. While specific comor-
bidities such as diabetic nephropathy may potentially have contributed to hypoglycaemia as an
endpoint in the included studies we were not able to explore this. Our focus is on the overall
burden of illness experienced by people with T2D in the form of a MM count. The impact of
specific conditions on outcomes in people with MM could be explored in future studies.
Conclusions
We have reviewed the existing literature to provide a comprehensive summary of the effects of
MM count in people with T2D on all-cause mortality and glycaemic outcomes. Our findings
show that MM is significantly associated with increased mortality and hypoglycaemia. How-
ever, the effects of MM on other measures of glycaemic control, particularly HbA1c, is mixed.
Our review findings emphasise the need for clinical guidelines and clinicians to support a
holistic approach to the complex care needs of those with T2D living MM, where care of the
whole person should be the primary concern, an approach that accounts for the full range of
conditions that people with T2D may be living with.
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